Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer

"PD-1/CTLA-4 Dual Functional Antibody (iparomlimab and tuvonralimab injection):~5 mg/kg intravenous infusion every 3 weeks (day 1 of each 21-day cycle) for up to 6 cycles, with potential for maintenance therapy continuation. Used in combination with GP regimen in experimental arm only. This is a novel dual-functional antibody targeting both PD-1 and CTLA-4 pathways simultaneously."

Gemcitabine 1000 mg/m² d1,8+Cisplatin 25mg/m² d1,8

10mg po d1-14 q3w

XELOX (oxaliplatin 130mg/m² d1+capecitabine 1000mg/m² d1-14 q3w) or FOLFOX6 (Oxaliplatin 85 mg/m², leucovorin 400 mg/m², fluorouracil 400 mg/m² intravenous bolus followed by fluorouracil 2400 mg/m² 46 hours, q2w)